In a real-life clinical set-ting , the percentage of patients reaching the combined endpoint of decreasing HbA@c > @ mmol/mol , without hypoglycaemia , peripheral oedema or treatment termination due to gastrointestinal side effects was higher after the addition of vildagliptin as compared to other antidiabetic agents with comparable rate of side effects .